CliffBio
small molecule

ASENAPINE MALEATE

ASENAPINE MALEATE

Loss of exclusivity—loss of exclusivity
CompanyAlembic →See this company's full patent-cliff portfolio

Drug detail

Brand nameASENAPINE MALEATE
Active ingredientASENAPINE MALEATE
StrengthEQ 2.5MG BASE
Dosage formTABLET
RouteSUBLINGUAL
ModalitySmall molecule
FDA approvalJuly 2021
Marketing statusRX

More from Alembic

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.